Hepregen, an MIT spinoff company developing a way to screen drugs in development for liver toxicity, has raised $3 million out of a $5 million first round of venture capital, according to a regulatory filing cited by Private Equity Hub. The backers of the company include Battelle Ventures and Innovation Valley Partners. Sangeeta Bhatia and Salman Khetani founded the company, according to this article in Technology Review.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
